Moderna Covid vaccine candidate almost 95% effective, trials show

US-based biotech firm is latest to reveal impressive results from phase 3 trials of jab Coronavirus - latest updates See all our coronavirus coverage The race for a coronavirus vaccine has received another shot in the arm with the US biotech firm Moderna becoming the latest to reveal impressive results from phase 3 trials of its jab. An interim analysis released on Monday, and based on 95 patients with confirmed Covid infections, found the candidate vaccine has an efficacy of 94.5%. The company ...